Food and Drug Administration, HHS.
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 11 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Approval is withdrawn as of November 30, 2020.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.
End Further Info
Start Supplemental Information
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
|ANDA 061884||Rifamate (isoniazid and rifampin) Capsules, 150 milligrams (mg); 300 mg||Sanofi-Aventis U.S. LLC 55 Corporate Dr., Bridgewater, NJ 08807.|
|ANDA 065196||Ceftazidime for Injection, 1 gram(g)/vial||Morton Grove Pharmaceuticals Inc./Wockhardt USA LLC., 6451 Main St., Morton Grove, IL 60053.|
|ANDA 065197||Cefotaxime for Injection, Equivalent to (EQ) 1 g base/vial; EQ 2 g base/vial; EQ 500 mg base/vial||Do.|
|ANDA 078229||Terbinafine Hydrochloride (HCl) Tablets, EQ 250 mg base||Do.|
|ANDA 081134||Niacin Tablets, 500 mg||Do.|
|ANDA 091659||Heparin Sodium Injection, 5,000 units/milliliter (mL)||CASI Pharmaceuticals, Inc., 9620 Medical Center Dr., Suite 300, Rockville, MD 20850.|
|ANDA 202647||Granisetron HCl Injection, EQ 0.1 mg base/mL (EQ 0.1 mg base/mL)||Yung Shin Pharmaceutical Industrial Co., Ltd./Carlsbad Technology, Inc., 5922 Farnsworth Ct., Carlsbad, CA 92008.|
|ANDA 202648||Granisetron HCl Injection, EQ 1 mg base/mL (EQ 1 mg base/mL); EQ 4 mg base/4 mL (EQ 1 mg base/mL)||Do.|
|ANDA 205173||Bosentan Tablets, 62.5 mg and 125 mg||Mylan Pharmaceuticals Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504.|
|ANDA 207843||Telmisartan Tablets, 20 mg, 40 mg, and 80 mg||Hisun Pharmaceutical (Hangzhou) Co., Ltd./Hisun Pharmaceuticals USA, Inc., 200 Crossing Blvd., 2nd Floor, Bridgewater, NJ 08807.|
|Start Printed Page 68889|
|ANDA 210681||Ranitidine HCl Capsules, EQ 150 mg base and EQ 300 mg base||Novitium Pharma LLC, 70 Lake Dr., East Windsor, NJ 08520.|
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of November 30, 2020. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on November 30, 2020 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
End Supplemental Information
Dated: October 26, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2020-24012 Filed 10-29-20; 8:45 am]
BILLING CODE 4164-01-P